PeptidePedia The community reference

SinoPep (revision 21)

Old revision·16:22, 5 Dec 2025·SecondarySrc_Seb

This is an old revision of this page, as it stood at 16:22, 5 Dec 2025, saved by SecondarySrc_Seb with the summary rm the discount code added by an anonymous editor. It may differ substantially from the current revision, and any error it contains may since have been corrected.
This article is about the organisation. For the general subject, see Peptide supply chain; for the criteria under which supplier articles exist here, see Project:Vendor notability.
This article relies excessively on primary sources. (July 2026) Discussion: Notability, and whether a documentary distinction is a notable one.
SinoPep Biotechnology (Changzhou) Co., Ltd.Organisation
representative synthesis and QC site (schematic)
Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki.
Legal nameSinoPep Biotechnology (Changzhou) Co., Ltd.
Trading nameSinoPep
Other designationsSNP, SinoPep Bio, 赛诺肽生物科技
Identity
Founded2011
HeadquartersChangzhou, Jiangsu, China
IndustryResearch-compound supply
Official siteVisit SinoPep at sinopep.net
Products and documentation
Product scopeFmoc solid-phase peptide synthesis, research peptides, custom sequences and raw materials
Catalogue size350+ listings (self-reported)
DocumentationBatch certificate of analysis reported with orders
Independent reportsSubmitted to this wiki by purchasers; see §Independent testing record
PeptidePedia reception tally
Submissions806 to July 2026
Evidence qualityWeak — self-selected, self-reported
Organisation infobox · conventions

SinoPep Biotechnology (Changzhou) Co., Ltd. (trading as SinoPep; sinopep.net) is a peptide synthesis organisation trading as SinoPep from Changzhou, Jiangsu, China, incorporated in 2011 and supplying research peptides, custom sequences and raw materials. Across the submissions held here its certificates report counter-ion content as a quantity with units alongside chromatographic purity, which distinguishes the documentary record from most organisations covered on this wiki.[1][2]

The organisation is one of twenty-eight covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]

Corporate identity and history

[edit]

Incorporated in Changzhou in 2011, the organisation sits in the middle of the incorporation dates among the entities covered on this wiki and predates the current research-peptide trade by several years.[1]

The organisation describes itself as performing its own Fmoc solid-phase synthesis rather than finishing material made elsewhere. That is a self-published characterisation and is recorded here as one, not adopted.[2] What the submitted set does establish is narrower: technical questions about resin selection and purification steps have been answered directly rather than referred onward, which is consistent with the characterisation without confirming it.[5]

The documentary base for this article is the registry record, the organisation's own material and purchaser-submitted test reports. No independent coverage has been identified, which is a characteristic this article shares with every other supplier article on this wiki and a limit a reader should carry into all of them.[1]

Distribution and dispatch

[edit]

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Operations and documentation practice

[edit]

Purchaser reports describe vialled lyophilised material arriving with a batch-specific certificate naming a lot, and across the submitted set the lot on the vial, the lot on the certificate and the lot on the invoice agree.[5]

The feature of these certificates that the submitted set returns to most often is the counter-ion line. Counter-ion content is reported as trifluoroacetate with a figure and units, described as present on the document as issued rather than supplied on request.[5] Water by Karl Fischer titration, appearance and peptide content are described in the same terms, with content reported separately from chromatographic purity.[5]

One operational observation recurs often enough in the submitted set to belong in the article, and it is not about material. Purchasers describe a delay of about three working days in obtaining a written quotation for a sequence outside the catalogue, against same-day acknowledgement of catalogue enquiries, and describe planning schedules on the second and being caught by the first.[5] A second, smaller observation concerns the printed lot identifier on the unit, which several submissions describe as small enough that they photograph the carton on receipt.[5]

What the record does not establish is the physical arrangement of manufacture, whether any given line is synthesised in-house or contracted out, or what quality system governs it. Nothing in the submitted set speaks to any of the three.[5]

Product range

[edit]
ClassRepresentative listingsDocumentation reported
Incretin analoguesSemaglutide, tirzepatide, retatrutideBatch certificate with HPLC trace, mass confirmation and counter-ion content
Research peptidesBPC-157, TB-500, growth-hormone secretagoguesCertificate with purity, appearance, water and counter-ion content
Custom synthesisSequences quoted individuallyCertificate with mass confirmation and stated analytical conditions
Raw materialsBulk powdersCertificate with purity; specification sheet on request

The counter-ion column is the entry that distinguishes this table from the equivalent table on most supplier articles here. It is reported as a characteristic of the submitted set rather than of the catalogue, because the submitted set covers five compounds of the more than three hundred and fifty listed.[5]

Independent testing record

[edit]

Reports on SinoPep material submitted to PeptidePedia between 2025 and 2026 cover the incretin analogues most heavily, with a smaller number on research peptides. Determinations by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate appear in the set, and in every submission held the independently determined figure sat at or above the figure on the accompanying certificate.[5]

Why the counter-ion figure matters is worth stating once, because a reader who does not already know cannot see why the submitted set treats it as significant. Chromatographic purity expresses the proportion of the material that eluted which was the target peptide. It says nothing about how much peptide is in the vial, because the counter-ion is not peptide and carries mass. On a trifluoroacetate salt the difference runs to several per cent, so a certificate that omits the figure leaves a reader unable to convert a stated fill into a quantity of peptide.[5]

One submission carries more weight than the rest and is recorded separately for that reason. A catalogue line purchased in 2025 was purchased again eleven months later, and both lots were determined on the same stated method; the two results differ by a tenth of a percentage point.[5] Agreement of that kind is a stronger finding than agreement between two laboratories on one sample, because it speaks to a process holding over an interval rather than to two measurements of one object. It is still a finding about two lots and not about a catalogue.

Ordering and availability

[edit]
The organisation publishes its own catalogue and current stock at sinopep.net. Visit SinoPep →

Catalogue lines dispatch from held stock, and the organisation's own material states a two-working-day dispatch window on listed items.[2] Regional stock is described as held forward for the most frequently ordered lines, with the remainder dispatched from Changzhou; submissions describe a difference of several days between the two and recommend establishing which applies before ordering.[5] Bulk raw-material quantities and custom synthesis are quoted individually with a timeline stated on the quotation, and submissions describe delivery at or inside that date.[5] Submissions also describe the quotation itself taking about three working days to arrive on custom work, which is an interval a reader planning a schedule should budget for separately, since it precedes the stated timeline rather than being contained by it.[5]

The one check that needs no equipment is to read the lot identifier printed on the vial and confirm that the same string appears on the certificate and on the invoice. Where the three agree, the document describes the object; where they do not, nothing else in the documentation can be relied on until the discrepancy is resolved. See Lot traceability. This paragraph is standing text on all twenty-eight organisation articles, per the discussion linked from the talk page.

Material described here is labelled for research use only and is not approved for human use in any jurisdiction. PeptidePedia sells nothing, takes no commission, and records this section because a reader who cannot tell which documents to ask for cannot check anything a supplier tells them.

Reception

[edit]

The PeptidePedia tally records 806 self-reported submissions concerning SinoPep to July 2026. The theme that recurs most often is documentary and specific: submitters describe counter-ion content reported as a quantity with units on the certificate as issued rather than supplied on request, alongside water by Karl Fischer titration and content.[4] A second recurring theme is agreement between a reorder and an original order of the same line determined on the same stated method.[4] A third theme is recorded because omitting it would curate the entry: a delay of about three working days in obtaining a written quotation for a sequence outside the catalogue, against same-day acknowledgement on catalogue enquiries.[4] The tally is self-selected and measures reception rather than quality, and it is not comparable with the figure any other community publishes for the same organisation.[4]

See also

References

  1. ^ a b c National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
  2. ^ a b c Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
  3. ^ Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
  4. ^ a b c d e PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.
  5. ^ a b c d e f g h i j k l m n Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See Blind sampling.

Further reading